he Japanese government is probing a scandal over allegations that Bayer may have improperly instructed a former sales rep to gather patient data that was used to prepare medical journal papers for promoting its Xarelto blood thinner, according to Pharma Japan.

The Ministry of Health, Labor, and Welfare is reportedly examining whether the company continued to use the papers — which might actually constitute promotional materials — after these were withdrawn in 2016. If Bayer had done so, the drug maker might have violated a law regarding false and misleading advertising, the web site explained.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy